110 related articles for article (PubMed ID: 2117828)
21. Analysis of the human immunodeficiency virus type 1 envelope protein interaction with the CD4 host cell receptor.
Malvoisin E; Wild F
J Gen Virol; 1994 Apr; 75 ( Pt 4)():839-47. PubMed ID: 8151300
[TBL] [Abstract][Full Text] [Related]
22. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.
Center RJ; Earl PL; Lebowitz J; Schuck P; Moss B
J Virol; 2000 May; 74(10):4448-55. PubMed ID: 10775580
[TBL] [Abstract][Full Text] [Related]
23. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
24. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor.
Platt EJ; Madani N; Kozak SL; Kabat D
J Virol; 1997 Feb; 71(2):883-90. PubMed ID: 8995604
[TBL] [Abstract][Full Text] [Related]
25. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
26. Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.
Mizukami T; Fuerst TR; Berger EA; Moss B
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9273-7. PubMed ID: 2461565
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
28. The transmembrane domain of vesicular stomatitis virus glycoprotein suffices to anchor HIV-1 envelope gp120 expressed by a recombinant vaccinia virus.
Jin Y; Wright SE
Int J Mol Med; 2003 Jul; 12(1):11-6. PubMed ID: 12792802
[TBL] [Abstract][Full Text] [Related]
29. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
[TBL] [Abstract][Full Text] [Related]
30. Expression and processing of the human immunodeficiency virus type 1 envelope glycoprotein.
Chen SS
Intervirology; 1996; 39(4):242-8. PubMed ID: 9078465
[TBL] [Abstract][Full Text] [Related]
31. Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.
Raja NU; Vincent MJ; Jabbar MA
J Gen Virol; 1993 Oct; 74 ( Pt 10)():2085-97. PubMed ID: 8409933
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.
Freed EO; Myers DJ; Risser R
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4650-4. PubMed ID: 2191297
[TBL] [Abstract][Full Text] [Related]
33. CD4 activation of HIV fusion.
Sattentau QJ
Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the D strand of the human CD4 V1 domain affect CD4 interactions with the human immunodeficiency virus envelope glycoprotein gp120 and HLA class II antigens similarly.
Piatier-Tonneau D; Gastinel LN; Moussy G; Bénichou B; Amblard F; Vaigot P; Auffray C
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6858-62. PubMed ID: 1713692
[TBL] [Abstract][Full Text] [Related]
35. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.
Hart TK; Kirsh R; Ellens H; Sweet RW; Lambert DM; Petteway SR; Leary J; Bugelski PJ
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2189-93. PubMed ID: 2006155
[TBL] [Abstract][Full Text] [Related]
36. Calcium requirement and inhibitor spectrum for intracellular HIV type 1 gp160 processing in cultured HeLa cells and CD4+ lymphocytes: similarity to those of viral envelope glycoprotein maturase.
Kamoshita K; Shiota M; Sasaki M; Koga Y; Okumura Y; Kido H
J Biochem; 1995 Jun; 117(6):1244-53. PubMed ID: 7490267
[TBL] [Abstract][Full Text] [Related]
37. Identification of three N-linked glycans in the V4-V5 region of HIV-1 gp 120, dispensable for CD4-binding and fusion activity of gp 120.
Hemming A; Bolmstedt A; Jansson B; Hansen JE; Travis B; Hu SL; Olofsson S
Arch Virol; 1994; 134(3-4):335-44. PubMed ID: 8129620
[TBL] [Abstract][Full Text] [Related]
38. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1).
Neurath AR; Strick N; Jiang S
Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549
[TBL] [Abstract][Full Text] [Related]
39. Vaccinia virus vectors for study of membrane fusion mediated by human immunodeficiency virus envelope glycoprotein and CD4.
Ashorn P; Berger EA; Moss B
Methods Enzymol; 1993; 221():12-8. PubMed ID: 8361369
[No Abstract] [Full Text] [Related]
40. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.
Berger EA; Lifson JD; Eiden LE
Proc Natl Acad Sci U S A; 1991 Sep; 88(18):8082-6. PubMed ID: 1896455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
